A Review on the Potential of Selected Phytopharmaceuticals for Central Nervous System Disorders

Review article

Abstract

The global burden of central nervous system disorders, including neurodegenerative, neuropsychiatric, and neuroinflammatory conditions, poses a critical public health challenge. Conventional synthetic therapeutics often present significant limitations, such as adverse side-effect profiles, narrow therapeutic indexes, and a lack of disease-modifying efficacy. Consequently, natural products derived from historical ethnomedical systems serve as an invaluable reservoir for drug discovery. Among these, Withania somnifera, Bacopa monnieri, Valeriana officinalis, Cinnamomum zeylanicum, and Rhodiola rosea have demonstrated profound neuroprotective, nootropic, and adaptogenic properties. These agents act by several molecular cascades rather than single-target interactions. The main neuroprotective pathways include the regulation of the hypothalamic-pituitary-adrenal axis, suppression of pro-inflammatory cytokines, enhancement of antioxidant enzyme expression, inhibition of acetylcholinesterase, and modulation of fundamental neurotransmitter systems such as GABAergic, serotonergic, and dopaminergic pathways. These phytopharmaceuticals demonstrate the capacity to prevent toxic protein aggregation, promote synaptic plasticity, and stimulate dendritic arborization. Preclinical investigations validate their systemic efficacy in animal models of Alzheimer's disease, Parkinson's disease, stroke, and chronic stress-induced cognitive decline. Human clinical trials increasingly substantiate their safety, tolerability, and therapeutic merit, although rare safety concerns such as transient cholestatic hepatotoxicity require vigilant monitoring. Combining these validated ethnopharmacological agents into contemporary neurology represents a promising strategy for developing novel, multi-target neurotherapeutics. Scientific validation through reverse pharmacology methods bridges the gap between empirical use and modern evidence-based clinical neurology, optimizing treatment outcomes for various neuropathological conditions